One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study

Table 2

Oral anticoagulant and antiplatelet agents and other cardiovascular medications in patients with AF and two subgroups of NVAF and VAF.

Medication	All AF cohort	NVAF (91.5%)	VAF; (8.5%)	value
Anticoagulant agents
DOACs, (%)	970 (48.0)	955 (51.6)	15 (8.8)	<0.0001
VKA, (%)	649 (31.1)	499 (27.0)	150 (87.7)	<0.0001
LMWH,(%)	46 (2.3)	46 (2.5)	0 (0)	0.07
None, (%)	355 (17.6)	349 (18.9)	6 (3.5)	<0.0001
Antiplatelet agents
Single agent, (%)	774 (38.3)	726 (39.3)	48 (28.0)	0.01
Dual agents, (%)	126 (6.2)	124 (6.7)	2 (1.2)	0.01
Single or dual agents, (%)	900 (44.6)	850 (46.0)	50 (29.2)	<0.0001
Antiarrhythmic and rate control medications
Amiodarone	387 (19.2)	358 (19.4)	29 (17.0)	0.51
Class I antiarrhythmic medications	38 (1.9)	36 (1.9)	2 (1.2)	0.72
Beta blockers, (%)	1619 (80.1)	1474 (79.7)	145 (84.8)	0.13
Digitalis, (%)	319 (15.8)	260 (14.1)	59 (34.4)	<0.0001
Nondihydropyridine CCB, (%)	219 (10.8)	210 (11.4)	9 (5.3)	0.02
Other cardiovascular medications
RAS inhibitors,(%)	781 (38.7)	741 (40.1)	40 (23.4)	<0.0001
Diuretics, (%)	792 (39.2)	712 (38.5)	80 (46.8)	0.04
Statins, (%)	753 (37.3)	715 (38.7)	38 (22.2)	<0.0001

AF: atrial fibrillation; chronic kidney disease; CCB: calcium channel blocker; DOACs: direct oral anticoagulant agents, LMWH: low molecular weight heparin; LVH: left ventricular hypertrophy; NVAF: nonvalvular AF; VAF: valvular AF. RAAS: renin angiotensin system blockers; VKA: vitamin K antagonists. Difference between NVAF and VAF patients. Transthoracic echocardiography was done for 90% of patients.